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Introduction
Blood platelets play a critical role in the cessation of bleeding upon vascular injury. However, they also contribute to the low-grade inflammation that drives endothelial dysfunction and the formation of occlusive thrombi upon atherosclerotic plaque rupture (1) . Under physiological conditions the continual release of inhibitory prostaglandins and nitric oxide by the endothelium prevents platelet activation and adherence to the vessel wall (2) . Upon vessel wall damage, platelets bind to exposed collagen, become activated and release a number of stimulatory mediators including adenosine diphosphate (ADP) which feedback in an autocrine manner (3) . The subsequent release of soluble platelet agonists promotes platelet aggregation to ensure rapid haemostasis at the site of injury and the formation of a stable clot, preventing further blood loss.
Platelet activation is a tightly regulated process with changes in platelet reactivity significantly impacting upon the haemostatic process. Increased platelet activity, for example at the site of atherosclerotic plaque rupture, may result in myocardial infarction or stroke.
Conversely decreased platelet activity is associated with an increased risk of bleeding.
Platelet G protein-coupled receptors (GPCRs) are critical regulators of platelet function with pharmacological blockade of these receptors a powerful therapeutic tool in the treatment and prevention of arterial thrombosis (4) . In order to optimise the use of existing antiplatelet drugs and to develop new therapies, more detailed knowledge of the molecular mechanisms that regulate GPCR-mediated platelet function is still required.
The platelet P2Y 12 receptora key player in platelet activation
Platelet activation is a multistep process consisting of platelet adhesion, shape change, granule secretion and aggregation. It is mediated by a number of cell surface receptors, including integrins and ion channels as well as GPCRs (3) . Of the GPCRs present on the platelet surface, the key receptors involved in platelet activation include the protease activated receptor (PAR)1 and PAR4, the purinergic P2Y 1 and P2Y 12 and the TP-α thromboxane (4) . The P2Y 12 receptor plays a pivotal role in platelet activation (reviewed in (1) ). Stimulation of P2Y 12 receptors by ADP released from the dense granules of activated platelets results in sustained platelet aggregation and secretion (5) . In addition, the P2Y 12 receptor plays an essential role in potentiating platelet responses initiated by other important platelet activators such as thrombin and thromboxane (6) . Pharmacological blockade of the P2Y 12 receptor is a powerful antiplatelet strategy in the treatment and prevention of arterial thrombosis associated with coronary atherosclerosis. Clopidogrel, prasugrel and ticagrelor are potent inhibitors of the P2Y 12 receptor with efficient antithrombotic activity reducing the rate of thrombotic events in acute coronary syndrome patients (7) .
In order to minimize inappropriate platelet recruitment and activation at the site of a growing thrombus, platelet ADP responsiveness is tightly regulated in human platelets (8) (9) (10) (11) (12) . P2Y 12 receptor responsiveness rapidly desensitizes in human platelets (13) . Previous studies in cell lines have identified that G protein-coupled receptor kinase (GRK)2-and GRK6-dependent phosphorylation of the P2Y 12 receptor is required for arrestin association and desensitization (9) . Following removal of ADP there is a rapid resensitization of P2Y 12 receptor responsiveness in human platelets (11) . In order to resensitize, the P2Y 12 receptor internalizes following agonist addition and then recycles back to the cell membrane following removal of ADP (11) . The P2Y 12 receptor, similarly to P2Y 1 , internalizes via clathrin-and dynaminmediated endocytosis (14) . Intriguingly these two purinergic receptors appear to sort into distinct membrane clathrin coated pits, an observation that has been reported for other GPCRs (15) . The mechanisms underlying P2Y 12 receptor internalization are complex and, as with receptor desensitization, are mediated in part by GRKs and arrestin (14, 16, 17) . The small GTP-binding protein ARF6 (ADP-ribosylation factor 6) also plays a role in the internalization of P2Y 12 receptors in human platelets (16) . Activation of P2Y 12 receptors stimulates ARF6 activity which in turn regulates Nm23-H1, an nucleoside diphosphate kinase to facilitate dynamin-dependent fission of clathrin-coated vesicles. Following internalization, the P2Y 12 receptor undergoes rab5-dependent trafficking to a sorting compartment from which it is rapidly recycled (18) . Rapid recycling of the P2Y 12 receptor had previously been described in human platelets although the mechanism at that time was unclear (8) . Blockade of receptor internalization or subsequent recycling results in attenuation of receptor resensitization in human platelets (11) . Our understanding of this process has been further advanced by the study of patients with rare genetic variations in the platelet P2Y 12 receptor.
Rare genetic variations in platelet GPCRs: shining a light into the receptor / structure function relationship in vivo
Genetic variations in GPCR genes that disrupt receptor function can lead to a wide variety of human genetic diseases (reviewed in (19)and (20) . Advances in genomic technologies have led to a substantial increase in the identification and characterization of naturally occurring rare and common GPCR variants. Such variants can include single-nucleotide polymorphisms (SNPs) and gene insertions or deletions with the potential to alter GPCR function and expression. In some cases these variants can inactivate receptor proteins, often referred to as loss-of-function (LOF) mutations (21). Heterozygous expression of LOF mutations can in some cases result in a dominant negative phenotype, with expression of the LOF variant impairing the function of the wild type receptor (as reviewed in (22)). In contrast to LOF mutations constitutively active mutants (CAMs) will lead to agonistindependent signalling. Both animal models and in vitro studies have commonly been used to characterize the molecular pathologies that underlie these naturally occurring GPCR mutations with inactive, overactive, or constitutively active receptors identified that result in pathology. Receptor variants may alter receptor expression, basal activity, ligand binding, Gprotein coupling, receptor desensitization and receptor recycling (21). An ever increasing variety of GPCRs are affected by genetic variation that results in human pathology (reviewed in (20) and (19)) including variations in platelet GPCRs affecting platelet function (reviewed in (22)).
The detailed and systematic study of patients with bleeding disorders has continued to provide significant information regarding platelet GPCR function(23). Indeed the P2Y 12 receptor was initially cloned following the study of a patient with a bleeding history and a loss of function variation in the P2Y12R gene that encodes P2Y 12 (24). As part of the Through this and similar patient-led phenotypic approaches, LOF variants in a number of platelet GPCRs including the P2Y 12 (see Figure 1 This review will concentrate on the consequences of mutations which specifically affect P2Y 12 R surface expression, internalization and traffic that have in turn provided important insights into how these clinically important GPCRs function in vivo.
The DRY motif: the case of the R122C P2Y 12 receptor variant
Recently solved agonist-and antagonist-bound crystal structures of a number of GPCRs including the P2Y 12 receptor(37,38) (39)have significantly enhanced our understanding of ligand / receptor interaction and revealed an overall receptor activation mechanism (40,41). A number of conserved regions show distinct interaction patterns in the inactive receptor (R) versus active receptor (R*) conformations (40,42,43). These motifs are believed to be critical regulators of the receptor activation process with one of these composed of the amino acids glutamic acid/aspartic acid-arginine-tyrosine, making up the E/DRY motif (44,45). This motif is located at the boundary between transmembrane helix 3 (TM3) and intracellular loop 2 (ICL2) and is one of the most highly conserved in class A rhodopsin-like GPCRs with the arginine (Arg) being found in close to 100% of these receptors (44), including the P2Y 12 receptor(45). The consensus derived mostly from studies on α 1B and β 2 adrenoceptors is that the basic Arg forms a stabilizing intrahelical salt-bridge with the neighbouring Asp or Glu, and interhelical hydrogen bonds with another charged residue at the base of TM6, thereby constraining the GPCR in an inactive (R) conformation(42,43).
The in vivo importance of the E/DRY motif was demonstrated in a patient who had a lifelong history of spontaneous bleeding, and haemorrhage upon surgical challenge (31). This patient who was homozygous for an Arg122Cys substitution within the DRY motif of the P2Y 12 receptor (DRYDCY) displayed significantly reduced platelet aggregation in response to ADP (see Figure 1 ). Further analysis of platelets derived from the patient revealed a significant reduction in surface P2Y 12 receptor expression. Two other class A GPCRs have also been identified with naturally occurring mutations in the central Arg of the DRY motif which include the vasopressin V2 (46) (47) and the gonadotropin-releasing hormone receptors (GnRH) (48,49). In the case of the GnRH receptor, two mutations (Arg139His or Arg139Cys) result in a loss of agonist-stimulated receptor activity and hypogonadotropic hypogonadism in the patient. For mutations in the V2 vasopressin receptor, the situation is more complicated with mutations in the DRY motif leading to two different diseases with opposite clinical outcomes. An Arg137His mutation leads to nephrogenic diabetes insipidus (50), while an Arg137Cys/Lys mutation leads to a nephrogenic syndrome of inappropriate antidiuresis (46). Intriguingly the P2Y 12 receptor crystal structure shows that this receptor lacks some regulatory features conserved in many class A GPCRs. For example an "ionic lock" between the bottom of TM3 and TM6 seen in some GPCRs (51) is not present in the P2Y 12 receptor (37). This lock is thought to stabilise the inactive conformation of a GPCR in the absence of agonist ligand. In line with these structural observations, close examination of P2Y 12 receptor signalling in 1321N1 cells shows that the receptor exhibits agonist-independent constitutive activity(31,52). Over-expression of the G i -coupled P2Y 12 receptor leads to an attenuation of forskolin-stimulated adenylate cyclase responsiveness in the absence of ADP (31) (52) . This reduction in forskolin responsiveness is even more pronounced in cells expressing the Arg122Cys P2Y 12 variant receptor. Similarly the Arg137Cys/Lys variants of the V2 vasopressin receptor are also characterized by an elevated basal agonist-independent signal (53) . Importantly ticagrelor is the only P2Y 12 receptor antagonist to block the constitutive agonist-independent activity of the wild type P2Y 12 receptor and may contribute to the improved clinical efficacy of this antiplatelet drug versus other clinically used P2Y 12 receptor antagonists (52) .
In relation to receptor traffic, the wild type P2Y 12 receptor undergoes significant agonistindependent internalization where it colocalizes with transferrin, a marker for early and recycling endosomes (31). This pool of receptor, which recycles in a rab4-dependent manner, can readily recycle back to the cell surface (18) . Whether like other platelet GPCRs (54, 55) this agonist-independent traffic may provide an internal pool of receptor able to mobilise to the cell surface and support receptor signalling requires further study. In cell lines the Arg122Cys P2Y 12 receptor also internalizes in an agonist-independent manner although at a faster rate than the wild type receptor(31). Interestingly, mutation in the DRY motif of the V2 vasopressin receptor (Arg137His) promotes agonist-independent internalization followed by intracellular accumulation (50). Like the Arg137His vasopressin receptor, the Arg122Cys P2Y 12 receptor variant undergoes rapid agonist-independent loss of surface receptor(31).
When combined with signalling data outlined above, disruption of the DRY motif therefore appears to prevent stabilization of the P2Y 12 and other GPCRs in an inactive conformation in the absence of agonist thereby enhancing agonist-independent receptor activity and internalization.
Following agonist-independent internalization a significant proportion of the Arg122Cys P2Y 12 receptor variant, as in platelets, accumulates intracellularly (31). For many variant GPCRs, including in platelets variants of the TP thromboxane receptor (35) and PAR4(33), the receptor accumulates in the Golgi/ER suggestive of an impairment of receptor export.
This was not the case with the Arg122Cys P2Y 12 variant receptor with no evidence of colocalization with Golgi/ER markers. In fact, the Arg122Cys P2Y 12 receptor variant is targeted to a distinct endocytic compartment, where unlike the wild type P2Y 12 receptor, it colocalizes with lysosomal markers (31). The specific molecular regulators of this process are currently unknown. The variant does possess a novel cysteine that could lead to the introduction of novel disulfide cysteine-cysteine intramolecular bonds potentially promoting this aberrant traffic. However no obvious differences in molecular masses of the Arg122Cys P2Y 12 receptor have been reported which would preclude lack of novel protein-protein bonds.
Further there are no obvious interaction motifs that could explain changes in receptor trafficking that are proximal to the DRY motif. Given the large number of interacting proteins that could potentially regulate the Arg122Cys P2Y 12 variant being preferentially targetted to lysosomes (56) , further detailed cellular studies are still required to address this question.
The integrity of the PDZ-binding motif of the P2Y 12 R is essential for normal platelet receptor function
A number of SNPs within GPCRs appear to modulate agonist-dependent receptor traffic. For example in the human β 1 -adrenoceptor Ser49Gly, a SNP located in the N-terminus, displays a distinct trafficking phenotype (57) with the variant exhibiting increased basal and agoniststimulated adenylyl cyclase activity as well as enhanced agonist-induced downregulation (58) . For the β 2 -adrenoceptor the picture is more complex with an Arg16Gly variant receptor displaying enhanced agonist-promoted downregulation whilst a Gln27Glu polymorphism is resistant to degradation (reviewed in (59) . Such SNPs that can alter agonist-dependent traffic have the potential to impact upon pharmacotherapy directed at these GPCRs. For example the Arg16Gly β 2 -adrenoceptor receptor, which is associated with reduced lung function and familial nocturnal asthma, is also commonly resistant to some β 2 -adrenoceptor agonists (60) .
This agonist resistance has been attributed to enhanced agonist-induced receptor loss.
Similarly a variant of the µ-opioid receptor (L83I) morphine is more liable to internalize in response to morphine, unlike the wild-type receptor that undergoes significantly less morphine-stimulated internalization (61) . The presence of this SNP within an individual may consequently affect the development of tolerance and analgesic responses. Therefore SNPs which can affect normal agonist-stimulated changes in surface receptor expression have the potential to alter drug responsiveness.
In relation to the platelet P2Y 12 receptor, a particularly novel mutation identified through GAPP was in a patient with mild bleeding who was heterozygous for a Pro341Ala substitution (32). This SNP was of particular interest since the mutation is located within a putative postsynaptic density 95/disc large/zonula occludens-1 (PDZ) binding sequence at the extreme C terminus of the P2Y 12 receptor (see Figure 1 ). PDZ ligands consist of a short amino acid sequence and are found at the extreme C-terminus of a large number of proteins including more than 30 GPCRs (56, 62) . These ligands can bind to a number of PDZ domaincontaining regulatory proteins with these interactions regulating various aspects of receptor function including stabilization, signaling and trafficking (62, 63) . P2Y 12 was not able to recycle and resensitize following agonist exposure (18, 32) . This was in contrast to the wild type receptor which recycles back to the cell surface in a rab4/11dependent manner rapidly following agonist-dependent internalization facilitating receptor resensitization (18) . Therefore the integrity of the PDZ-ligand of the P2Y 12 receptor was essential for normal agonist-induced traffic.
PDZ-binding proteins play an essential role in maintaining platelet P2Y 12 R activity
Given the in vivo demonstration of the critical importance of the PDZ-binding motif, a subsequent proteomic screen revealed a series of binding partners that specifically interacted with the C-terminus of the P2Y 12 receptor including the PDZ-binding protein, Na+/H+ exchanger regulatory factor (NHERF). Interestingly the PDZ ligand and the presence of the Pro341 residue limited the number of proteins capable of interacting with the P2Y 12 Further studies have confirmed the ability of NHERF isoforms (NHERF1 and NHERF2) to bind specifically to the C-tail PDZ ligand of the P2Y 12 receptor (64), thus supporting the proteomic screen. These proteins have now been shown to regulate the surface expression and activity of numerous GPCRs (65) . NHERF1 interacts basally with the P2Y 12 receptor in a PDZ-dependent manner with agonist addition increasing P2Y 12 receptor / NHERF association that is required for agonist-stimulated receptor internalization (64) . Intriguingly agonistdependent association of the P2Y 12 receptor with NHERF was PDZ ligand-independent and required arrestin-receptor interaction. This study was therefore the first to directly demonstrate arrestin-dependent recruitment of NHERF1 to a receptor following agonist treatment. The in vivo significance of the NHERF-P2Y 12 
Variations in GPCR accessory proteins and their links to disease
The identification of genetic variants in key proteins that are essential for GPCR activity has also provided important insights into their functional significance. There are many examples of genetic variations in accessory proteins that disrupt receptor function linked to disease.
Examples include variants of Gβ subunits which are linked to essential hypertension, obesity, stroke, and myocardial infarction or variants of regulators G protein signalling (RGS) protein that confer risk for essential hypertension through changes in dopamine D1 receptormediated kidney function (reviewed in (66) .
In relation to GRKs, which are established regulators of GPCR activity and traffic, both human GRK2 and GRK3 genes appear to lack genetic variation in their coding regions whilst GRK4 and GRK5 possess variations that have significant functional impacts (reviewed in (67)). Variants of GRK4, altering dopamine D 1 receptor-mediated kidney function, have been identified as playing a role in essential hypertension (68) (69). Expression of three GRK4 SNPs (Arg65Leu, Ala142Val, and Ala486Val) increased basal phosphorylation of the dopamine D 1 receptor and impaired receptor-mediated cAMP production (70) . Further in vitro studies suggest that the GRK4 SNPs disrupt the function of dopamine D 1 receptors (71) (72), increase blood pressure, and impair the diuretic and natriuretic effects of dopamine D 1 receptor stimulation (73) . In addition to abnormal desensitization of the dopamine D 1 receptor, GRK4 polymorphisms are associated with increased expression of the angiotensin II type 1 receptor, which is another regulator of sodium load (74) .
A GRK5 variant (Leu41Gln), which displays an enhanced ability to promote agonistdependent β1 and β2 adrenoceptor desensitization and internalization, has been shown to be involved in accelerated termination of β-adrenoceptor-induced cardiac contractility, improved protection against cardiac β-adrenoceptor overstimulation, better response to β-blockers and improved survival in heart failure (75, 76) . Interestingly in GRK5, this polymorphism is adjacent to a calmodulin-binding domain (77) which, following calcium-calmodulin binding, is reported to inhibit GRK5 catalytic activity towards receptors.
Beyond GRKs, variations in other proteins known to regulate GPCR traffic have also been reported. Unlike the examples of GRK isoforms above, GPCRs share common endocytic trafficking of many cell surface expressed proteins. Therefore it is perhaps not surprising that specific mutations in key regulatory machinery components have more global effects on a plethora of cell surface cargo cell rather than just specific GPCRs. For example, sorting nexin 27 (SNX27) is a known regulator of endosomal recycling of specific PDZ ligand-containing cargo proteins including a number of GPCRs such as the β2-adrenoceptor, 5HT 2 receptor and parathyroid hormone receptor (78) (79) (80) . Detailed proteomic analysis conducted in mammalian cell lines has revealed that a loss of SNX27 expression results in the downregulation of multiple membrane proteins (81) . Recent evidence has linked mutations in the SNX27 gene to Down's syndrome and infantile myoclonic epilepsy (82) (83) . The molecular mechanism of Down's syndrome (DS) pathogenesis, particularly cognitive defects in DS mice models, are thought to be due to loss of SNX27 expression and the subsequent downregulation of membrane glutamate NMDA and AMPA receptors (82) .
Similarly mutations in the GTPase dynamin 2, which again regulates the membrane traffic of multiple cell surface proteins including that of GPCRs, are associated with a number of disorders including Charcot-Marie-Tooth (CMT), peripheral neuropathy and centronuclear myopathy (CNM) (84, 85) . These two genetically heterogeneous disorders, which are both associated with general skeletal muscle weakness, have differing pathophysiological origins.
Intriguingly close examination of the location of specific mutations in dynamin-2 revealed that most CNM mutations cluster in the interface between the dynamin mid-domain and pleckstrin homology domain of dynamin-2, thus altering the autoinhibitory interface between these domains thereby supporting a gain-of-function mechanism (86) . The CMT mutations meanwhile are predominantly located on phosphoinositide-binding PH domain loops which are essential for targeting dynamin-2 to the plasma membrane (87) . Given that the dynamin-2 knockout mouse is embryonic lethal (88), when combined, these studies suggest that mutations found in humans do not completely abolish dynamin-2 protein function, but rather involve subtle functional changes that lead to the progressive pathologies seen in CMT and CMN. Notably the examples of both SNX27 and dynamin-2 have validated the key physiological importance of these proteins and helped to validate the functional significance of key domains predicted to regulate their biology. Intriguingly given that arrestins play keys roles in receptor biology, very few genetic polymorphisms have been identified (67) . Some evidence has emerged that associates noncoding variations in the non-visual arrestin gene with the risk of developing major depressive disorder (89) and the pathogenesis of Alzheimer's disease (90) . So far coding polymorphisms with significant functional impact have only been discovered in the visual arrestin-1 gene, which lead to visual disorders (e.g., Oguchi's disease (91) , night blindness or retinitis pigmentosa(92)). Given both the physiological importance of the arrestin family in the regulation of the majority of GPCRs and that there are only two isoforms of the non-visual arrestins, perhaps it is not surprising that evolution may not have allowed for high levels of genetic variation of these proteins seen in GPCRs.
A number of SNPs linked to platelet GPCR function and traffic have been identified during the course of the GAPP study (unpublished data). These include variants in dynamin-2 and NHERF1. Further study is now required to determine the functional significance of these SNPs in relation to platelet GPCR function.
Conclusions and future perspectives
As highlighted above with studies on the P2Y 12 receptor, the investigation of naturally occurring GPCR variants continues to provide invaluable insights into the role of specific receptors as genetic risk factors for disease and the prediction of altered drug response. The identification of naturally occurring variants in accessory proteins that regulate GPCR traffic and function is ongoing. Inherent difficulties have limited our ability to translate our current understanding of the role of specific molecular regulators of receptor function from cell expression studies into animal models and then into man. For example significant differences in cell machinery, membrane trafficking and receptor expression levels exist in individual cell types. Further, technologies emerging from next-generation sequencing continue to generate significant datasets for integrating genomic information into pharmacogenomic studies. For example RNA-sequencing, which makes use of nextgeneration sequencing to assess RNA presence and quantity at a given time will enable the simultaneous profiling of multiple readouts including splice variants, expressed genes and RNA-edited isoforms. Such developments will significantly add to the already large list of protein variants, including those in GPCRs and their regulators identified over the past two decades. Whether specific genetic variations in key regulators of GPCR activity and traffic will provide an adjunct to the conventional routes of translating in vitro cell line studies into an in vivo physiologically relevant setting remains a potentially exciting opportunity to be fully realized.
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